(±)-1-P-TOLYL-3-AZABICYCLO(3.1.0)HEXANE
Diabetic Peripheral Neuropathy
XTL BiopharmaceuticalsSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
28 Active assets in the Diabetic Peripheral Neuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Duloxetine Aga Khan University | Phase 4 | A |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | BBB |
Duloxetine Eli Lilly and Company | Phase 4 | BBB |
ds-5565 Bangladesh Medical University | Phase 4 | BBB |
Capsaicin Corporacion Parc Tauli | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
(±)-1-P-TOLYL-3-AZABICYCLO(3.1.0)HEXANE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →